Research Use Only
HAUZ Research supplies compounds strictly for in-vitro laboratory use. Please confirm each statement before entering the site.
By entering, you agree to our Terms of Service.
Leave siteHarvard professor David Sinclair’s lab has demonstrated that aging is not simply wear and tear — it is an information problem. In 2026, the FDA cleared the first human trial of cellular reprogramming technology. Here is what that means for longevity research, and how peptides fit into the picture.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) has been studied extensively for its role in collagen and glycosaminoglycan synthesis, antioxidant gene expression, and skin barrier repair. It is one of the highest-volume compounds in the cosmetic research segment and among the most cited peptides in dermatological literature.
KLOW is a proprietary research blend developed by HAUZ Research combining four well-characterized peptides: BPC-157 (10mg), TB-500 (10mg), GHK-Cu (50mg), and KPV (10mg). Each component has been independently studied for tissue repair, anti-inflammatory, or regenerative properties, and the blend is designed for researchers studying multi-pathway approaches to tissue biology.
The BPC-157/TB-500 research blend combines BPC-157 and TB-500 (synthetic thymosin beta-4) in a single lyophilized preparation. Both have been studied for tissue repair in preclinical models, through different pathways.
TB-500 is the name most often used for a synthetic version of Thymosin Beta-4 (Tβ4), an actin-binding protein found in almost every cell. Preclinical research has examined its role in cell migration, angiogenesis and tissue repair.
GHK-Cu (Glycine-Histidine-Lysine Copper complex) is a naturally occurring copper-binding tripeptide first isolated from human plasma. It has been studied extensively for its role in wound healing, collagen synthesis regulation, and anti-inflammatory signaling in preclinical and in vitro models.
KPV (Lys-Pro-Val) is a synthetic tripeptide corresponding to the C-terminal amino acids 11-13 of alpha-melanocyte stimulating hormone (α-MSH). It has been studied in preclinical models for its anti-inflammatory properties and potential role in gut barrier function, and was among the compounds reviewed by the FDA’s Pharmacy Compounding Advisory Committee in July 2026.
News & Updates
Your cart is currently empty!
News & Updates
Subscribe to the latest updates and news.
Notifications